medigraphic.com
ISSN 0016-3813 (Print)

2005, Number 3

<< Back Next >>

Gac Med Mex 2005; 141 (3)

Familial hypertriglyceridemia and diabetes mellitus type 2.

Aguilar-Salinas CA, Ramírez-Moguel E, Gallegos-Martínez J, Leyva O, Oseguera J Lozano H, Gómez-Pérez F

Language: Spanish
References: 22
Page: 201-206
PDF size: 46.12 Kb.


ABSTRACT

Hypertriglyceridemia is a cardiovascular risk factor in type-2 diabetes. However, this abnormality may be caused by several mechanisms. In familial hypertriglyceridemia, a hyperlipidemia associated with type-2 diabetes, plasma accumulation of non atherogenic particles explains the presence of hypertriglyceridemia. Our objective was to compare the prevalence of coronary insufficiency and carotid artery stenosis in patients with type-2 diabetes with or without familial hypertriglyceridemia. Controls were paired against cases based on age, gender, diabetes duration, treatment and other cardiovascular risk factors. Controls had either a normal lipid profile (n=48) or hyperlipidemia (n=15). The intima-media thickness of the carotid arteries was significantly lower in cases compared to controls (0.55±0.12 vs 0.63±0.22 in normolipidemic controls and 0.66 ±0.18 mm in hyperlipidemic subjects (p=0.02)). Exercise treadmill testing was abnormal in a similar proportion of cases and controls (4.8 vs 6.2%). Incidence of cardiovascular complications was not different between groups. We therefore conclude that severe hypertriglyceridemia due to familial hypertriglyceridemia is not associated with an increased prevalence of symptomatic atherosclerosis in patients with type-2 diabetes.


REFERENCES

  1. Krolewky AS. Epidemiology of late complications of diabetes mellitus. En Joslin´s diabetes mellitus. Kahn CR, Weir GC (Eds). Lea & Febiger. 13a Edición Philadelphia, 1994, pp 610-617.

  2. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Research 2001;42:1298-307.

  3. Austin M, Hokanson JE, Edwards K. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A):7B-12B

  4. Ballantyne C, Grundy SM, Oberman A, Kreisberg R, Havel R, Frost P, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endoc Metab 2000;5:2089-2112.

  5. Assmann G, Brewer HB. Genetic (primary) forms of hypertriglyceridemia. Am J Cardiol 1991;68:13a-16a.

  6. Austin M, McKnight B, Edwards K, Bradley C, McNeely M, Psaty B, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20 year prospective study. Circulation 2000;101:2777-2782.

  7. Kissebah AH, Alfaarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: Normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism 1981;30:856-868.

  8. Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.

  9. Gibbons RJ, Balady, Beasley JW. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines. Circulation 1997;96:345-354.

  10. Pignoli P, Tremoli E, Poli A. Intimal plus medial thickness of artery wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-1406.

  11. Austin MA, Hokanson JE. Epidemiology of triglycerides, small dense low density lipoprotein and lipoprotein (a) as risk factors for coronary heart disease. Med Clin North Am 1994;78:99-115.

  12. Brunzell JD. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313-320.

  13. Eisenberg S. Lipoprotein abnormalities in hypertriglyceridemia: significance in atherosclerosis Am Heart J 1987;113:555-561.

  14. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis 1994; 110 (Suppl): S23-S26.

  15. van Barlingen HH, Kock LA, de Man FH, Erkelens DW, de Bruin TW. In vitro lipolysis of human VLDL:effect of different VLDL composition in normolipidemia, familial combined hyperlipidemia and familial hypertrygliceridemia. Atherosclerosis 1996:121:75-84.

  16. Otto C, Ritter M, Richter W, Minkenberg R, Schwandt P. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerosis risks. Metabolism 2001;50:166-170.

  17. Bartens W, Rader DJ, Talley G, Brewer HB. Decreased plasma levels of lipoprotein (a) in patients with hypertriglyceridemia. Atherosclerosis 1994;108:149-157.

  18. Beckman J, Creager M, Libby P. Diabetes and atherosclerosis. JAMA 2002;287:2570-2581.

  19. Howard B, Rodriguez B, Bennett P, Harris M, Hamman R, Kuller L. Prevention conference VI. Diabetes and cardiovascular disease. Circulation 2002;105:e132-152.

  20. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26 (Suppl 1):S83-S86.

  21. Yarnell JWG, Patterson CC, Sweetnam PM, Thomas HF, Bainton D, Elwood PC, et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease?. Ten-year follow- up of Caerphilly and Speedwell Cohorts. Arterios Thromb Vasc Biol 2001;21:1340-45.

  22. Gaw A. Evidence based approach for the management of mixed hyperlipidemia. Atherosclerosis 1998; 137 Suppl:S97-S100.




2020     |     www.medigraphic.com